JP6588397B2 - 高力価のｅ型肝炎ウイルスストックを生成する方法及びｅ型肝炎ウイルスの力価測定アッセイ - Google Patents

高力価のｅ型肝炎ウイルスストックを生成する方法及びｅ型肝炎ウイルスの力価測定アッセイ Download PDF

Info

Publication number
JP6588397B2
JP6588397B2 JP2016144065A JP2016144065A JP6588397B2 JP 6588397 B2 JP6588397 B2 JP 6588397B2 JP 2016144065 A JP2016144065 A JP 2016144065A JP 2016144065 A JP2016144065 A JP 2016144065A JP 6588397 B2 JP6588397 B2 JP 6588397B2
Authority
JP
Japan
Prior art keywords
hev
reaction mixture
copies
hepg2
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016144065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017023143A (ja
JP2017023143A5 (enExample
Inventor
ブレット・ブノ
テリー・ジャーニガン
ジョアン・ホッタ
マイケル・バーディック
Original Assignee
グライフォルス・ス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グライフォルス・ス・アー filed Critical グライフォルス・ス・アー
Publication of JP2017023143A publication Critical patent/JP2017023143A/ja
Publication of JP2017023143A5 publication Critical patent/JP2017023143A5/ja
Application granted granted Critical
Publication of JP6588397B2 publication Critical patent/JP6588397B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016144065A 2015-07-23 2016-07-22 高力価のｅ型肝炎ウイルスストックを生成する方法及びｅ型肝炎ウイルスの力価測定アッセイ Active JP6588397B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195936P 2015-07-23 2015-07-23
US62/195,936 2015-07-23

Publications (3)

Publication Number Publication Date
JP2017023143A JP2017023143A (ja) 2017-02-02
JP2017023143A5 JP2017023143A5 (enExample) 2018-09-06
JP6588397B2 true JP6588397B2 (ja) 2019-10-09

Family

ID=56409494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016144065A Active JP6588397B2 (ja) 2015-07-23 2016-07-22 高力価のｅ型肝炎ウイルスストックを生成する方法及びｅ型肝炎ウイルスの力価測定アッセイ

Country Status (22)

Country Link
US (1) US10208291B2 (enExample)
EP (1) EP3121267B1 (enExample)
JP (1) JP6588397B2 (enExample)
KR (1) KR102154380B1 (enExample)
CN (1) CN106367397B (enExample)
AR (1) AR106015A1 (enExample)
AU (1) AU2016204734B2 (enExample)
BR (1) BR102016016677A2 (enExample)
CA (1) CA2937088C (enExample)
CL (1) CL2016001768A1 (enExample)
ES (1) ES2669021T3 (enExample)
HU (1) HUE036699T2 (enExample)
IL (1) IL246634B (enExample)
MX (1) MX375106B (enExample)
MY (1) MY176204A (enExample)
NZ (1) NZ722213A (enExample)
PL (1) PL3121267T3 (enExample)
PT (1) PT3121267T (enExample)
RU (1) RU2691123C1 (enExample)
SG (1) SG10201605867UA (enExample)
TW (1) TWI666322B (enExample)
UY (1) UY36778A (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102158641B1 (ko) * 2019-03-06 2020-09-22 대한민국 야누스 인산화효소 저해제 및 헥사디메트린 브로마이드를 포함하는 바이러스 배양용 조성물 및 이를 이용한 바이러스 배양 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
WO2003001198A1 (en) * 2001-06-21 2003-01-03 Regents Of The University Of California Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase
WO2007046962A2 (en) * 2005-09-02 2007-04-26 The University Of Maryland, Baltimore Cell lines harboring hepatitis virus and methods for using thereof
AU2009298371A1 (en) * 2008-10-03 2010-04-08 The Rockefeller University New HCV entry factor, Occludin
EP2663328B1 (en) * 2011-01-10 2018-09-19 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Infectious hepatitis e virus genotype 3 or 1 recombinants
CA2838749A1 (en) * 2011-06-10 2012-12-13 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy

Also Published As

Publication number Publication date
KR20170012140A (ko) 2017-02-02
PL3121267T3 (pl) 2018-07-31
TWI666322B (zh) 2019-07-21
RU2691123C1 (ru) 2019-06-11
MX2016009048A (es) 2017-01-23
CN106367397A (zh) 2017-02-01
PT3121267T (pt) 2018-04-26
AR106015A1 (es) 2017-12-06
TW201704468A (zh) 2017-02-01
IL246634A0 (en) 2016-12-29
EP3121267B1 (en) 2018-03-28
BR102016016677A2 (pt) 2019-02-12
ES2669021T3 (es) 2018-05-23
IL246634B (en) 2020-08-31
JP2017023143A (ja) 2017-02-02
US10208291B2 (en) 2019-02-19
HUE036699T2 (hu) 2018-07-30
MY176204A (en) 2020-07-24
CA2937088A1 (en) 2017-01-23
AU2016204734A1 (en) 2017-02-09
CA2937088C (en) 2022-06-21
UY36778A (es) 2016-09-30
CL2016001768A1 (es) 2017-05-12
KR102154380B1 (ko) 2020-09-10
CN106367397B (zh) 2021-07-20
SG10201605867UA (en) 2017-02-27
MX375106B (es) 2025-03-06
US20170022481A1 (en) 2017-01-26
NZ722213A (en) 2019-04-26
AU2016204734B2 (en) 2019-11-21
EP3121267A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
Zhou et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin
Dimitrov et al. A robust and cost-effective approach to sequence and analyze complete genomes of small RNA viruses
Hall et al. Evaluation of rapid and simple techniques for the enrichment of viruses prior to metagenomic virus discovery
Lau et al. Isolation and characterization of a novel Betacoronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from domestic rabbits
Sridhar et al. A systematic approach to novel virus discovery in emerging infectious disease outbreaks
Gillim-Ross et al. Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR
Law et al. Identification of hepatotropic viruses from plasma using deep sequencing: a next generation diagnostic tool
US20240117451A1 (en) Spike-in reference standard for use in detecting sample target from dna or rna organism
Brussel et al. Use of a new RNA next generation sequencing approach for the specific detection of virus infection in cells
US20080261198A1 (en) Diagnostic Primers and Method for Detecting Avian Influenza Virus Subtype H5 and H5n1
Yan et al. Comparison of seven commercial severe acute respiratory syndrome coronavirus 2 nucleic acid detection reagents with pseudovirus as quality control material
Yang et al. Circular RNA profiling reveals abundant and diverse circRNAs of SARS-CoV-2, SARS-CoV and MERS-CoV origin
Alvarado et al. Detection of Massachusetts and Arkansas serotypes of infectious bronchitis virus in broilers
JP6588397B2 (ja) 高力価のｅ型肝炎ウイルスストックを生成する方法及びｅ型肝炎ウイルスの力価測定アッセイ
CN113186226B (zh) Rna病毒核酸检测参照标准品及其用途
Jung et al. First outbreak of respiratory disease associated with swine influenza H1N2 virus in pigs in Korea
KR102260264B1 (ko) 코로나바이러스 질병 2019(COVID-19)의 SARS-CoV-2에 대한 실험실-안전 및 저비용 검출 프로토콜
HK1230654A1 (en) Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus
HK1230654B (en) Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus
WO2006132601A1 (en) Diagnostic primers and method for detecting avian influenza virus subtype h5 and h5n1
CN117925540B (zh) 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN117230258B (zh) 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法
CN116042913A (zh) 通用型流感病毒全基因组扩增、富集、测序的引物组合物及其应用
Trende et al. Barcoded SARS-CoV-2 viruses define the impact of time and route of transmission on the transmission bottleneck in a Syrian hamster model
Agerlin et al. Experimental inoculation of pigs with porcine respirovirus type 1 revealed pathological manifestations in the upper respiratory tract

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190912

R150 Certificate of patent or registration of utility model

Ref document number: 6588397

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250